|  |  |
| --- | --- |
| **Supplementary Table 1 .** Antiviral therapy administered to each patient. |  |
| **Genotype** | **Treatment** | **Time treatment** |
| 1a | Paritaprevir (150mg/24h) + Ombitasvir (25mg/24h) + Dasabuvir (250mg/12h) + Ribavirina (200mg/24h) | 12 weeks |
| 1a | Grazoprevir (100mg/24h) + Elbasvir (50mg/24h) | 24 weeks |
| 1a | Grazoprevir (100mg/24h) + Elbasvir (50mg/24h) | 12 weeks |
| 1a | Grazoprevir (100mg/24h) + Elbasvir (50mg/24h) | 12 weeks |
| 1b | Asunaprevir (100mg/24h) + Daclatasvir (60mg/24h) | 24 weeks |
| 1b | Asunaprevir (100mg/24h) + Daclatasvir (60mg/24h) | 24 weeks |
| 1b | Grazoprevir (100mg/24h) + Elbasvir (50mg/24h) | 12 weeks |
| 1b | Grazoprevir (100mg/24h) + Elbasvir (50mg/24h) | 12 weeks |
| 1b | Grazoprevir (100mg/24h) + Elbasvir (50mg/24h) | 12 weeks |
| 1b | Paritaprevir(150mg/24h) + Ombitasvir (25mg/24h) + Dasabuvir (250mg/12h) | 12 weeks |
| 1b | Paritaprevir(150mg/24h) + Ombitasvir (25mg/24h) + Dasabuvir (250mg/12h) | 12 weeks |
| 1b | Paritaprevir(150mg/24h) + Ombitasvir (25mg/24h) + Dasabuvir (250mg/12h) | 12 weeks |
| 1b | Paritaprevir(150mg/24h) + Ombitasvir (25mg/24h) + Dasabuvir (250mg/12h) | 12 weeks |
| 1b | Paritaprevir(150mg/24h) + Ombitasvir (25mg/24h) + Dasabuvir (250mg/12h) | 12 weeks |
| 1b | Paritaprevir(150mg/24h) + Ombitasvir (25mg/24h) + Dasabuvir (250mg/12h) | 12 weeks |
| 1b | Paritaprevir(150mg/24h) + Ombitasvir (25mg/24h) + Dasabuvir (250mg/12h) | 12 weeks |
| 2c | Sofosbuvir (400mg/24h) + Daclatasvir (60mg/24h) | 24 weeks |
| 3 | Sofosbuvir (400mg/24h) + Daclatasvir (60mg/24h) | 24 weeks |
| 3 | Sofosbuvir (400mg/24h) + Daclatasvir (60mg/24h) | 24 weeks |
| 4a | Simeprevir (150mg/24) + Daclatasvir (60mg/24h) | 12 weeks |

**Supplementary Table 2 .** Evolution of liver test and inflammatory parameters during the study period

|  |  |  |
| --- | --- | --- |
|  |  |  |
|   | **AST(IU/L)** | **ALT(IU/L)** | **Bilirubin(mg/dL)** | **ALP(IU/L)** | **GGT(IU/L)** | **CRP(mg/mL)** |
| -3m |  37.8 ± 19.4 | 49.2 ± 47.8 | 0.38 ± 0.2 | 228 ± 274 | 94.7 ± 202 | 0.85 ± 1.5 |
| -2m |  34.0 ± 14.1 | 39.1 ± 32.6 | 0.36 ± 0.2 | 211 ± 259 | 87.4 ± 179 | 0.86 ± 1.1 |
| -1m |  34.0 ± 14.7 | 41.7 ± 36.4 | 0.39 ± 0.2 | 222 ± 274 | 80.3 ± 154 | 0.60 ± 0.8 |
| Baseline |  36.2 ± 18.7 | 42.4 ± 45.5 | 0.46 ± 0.3 | 216 ± 303 | 82.1 ± 198 | 1.76 ± 3.6 |
| +1m |  20.0 ± 8.1\*\* |  22.4 ± 21.3\* | 0.48 ± 0.3 | 230 ± 318 | 33.2 ± 46 | 0.68 ± 0.8 |
| +2m |  18.0 ± 6.6\*\* |  18.5 ± 14.2\* | 0.40 ± 0.2 | 210 ± 252 | 23.1 ± 18 | 0.88 ± 1.4 |
| +3m |  18.1 ± 6.1\*\* | 15.4 ± 8.8\* | 0.43 ± 0.2 | 176 ± 133 | 19.8 ± 13 | 0.57 ± 0.6 |
| +4m |  15.7 ± 4.6\*\* | 13.9 ± 6.5\* | 0.40 ± 0.2 | 140 ± 93 | 20.5 ± 14 | 0.98 ± 1.3 |
| +5m |  16.3 ± 5.3\*\* | 13.4 ± 4.8\* | 0.39 ± 0.2 | 138 ± 92 | 22.6 ± 18 | 0.69 ± 0.8 |
| +6m |  16.0 ± 4.5\*\* | 14.3 ± 6.4\* | 0.37 ± 0.2 | 132 ± 79 | 21.4 ± 17 | 0.87 ± 1.2 |
| +7m |  17.2 ± 4.1\*\* | 14.2 ± 4.7\* | 0.36 ± 0.2 | 133 ± 75 | 22.6 ± 20 | 0.76 ± 1.1 |
| +8m |  17.2 ± 5.1\*\* | 14.5 ± 4.2\* | 0.36 ± 0.2 | 126 ± 68 |  21.7 ± 22  | 0.47 ± 0.6 |
| +9m |  17.5 ± 4.8\*\* | 14.9 ± 6.7\* | 0.34 ± 0.2 | 124 ± 56 | 24.1 ± 22 | 0.51 ± 0.7 |
| +10m |  17.7 ± 6.5\*\* | 14.2 ± 5.1\* | 0.35 ± 0.2 | 132 ± 76 | 24.9 ± 23 | 0.80 ± 0.9 |
| +11m |  17.8 ± 4.5\*\* | 14.7 ± 5.8\* | 0.32 ± 0.2 | 134 ± 66 | 23.0 ± 19 | 0.74 ± 1.1 |
| +12m |  16.9 ± 5.0\*\* | 13.5 ± 4.1\* | 0.35 ± 0.2 | 129 ± 74 |  22.9 ± 22 | 0.73 ± 0.9 |
| \* p < 0,05 respect to baseline; \*\* p < 0,001respect to baseline  |  |  |
| AST: Aspartate Aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline Phosphatase; GGT: Gamma glutamyltransferase. |